Analyzing Multiple Biomarkers with IHC: putting a 6-plex kit to the challenge
On November 16, 2021 Cerba Research and Akoya Biosciences held a webinar on how to analyze multiple biomarkers using Immunohistochemistry (IHC). The session was a deep dive in the Tissue Microenvironment (TME) with multiplex IF (Opal™) technology, discovering how to visualize, analyze, and quantify multiple phenotypes in situ.
As part of a long-standing collaboration with Akoya Biosciences, we agreed to test our pre-validated 6-plex panel kits, including one suitable for carcinoma immune-contexture investigations (CD8, CD68, FoxP3, PD1, PD-L1, PanCK). We were also able to put into practice Akoya’s pre-set imaging protocol on the Vectra® Polaris™ and related data analysis algorithm with inForm® software.
- Ivan Masetto, PhD, Field Application Scientist South of Europe at Akoya Biosciences
- Maroua Tliba, Image Analyst at Cerba Research
The Value of Biomarkers from Discovery to Commercialization
Why do some patients respond to therapy while others do not? The answer can be found in the concept of biomarkers: objective, measurable indicators of the
presence or severity of disease. Used for decades to aid medical diagnosis, researchers today use biomarkers in every phase of drug discovery and development.
There’s good reason. Biomarkers can triple drug development success rates, accelerating the availability of new therapeutics.
Download our article by Jérôme Sallette, CSO at Cerba Research, to learn more on the advantages of biomarkers in clinical research.
CerbACT Asia – Center of Excellence in Immuno-Oncology
CerbACT Asia empowers precision medicine development and drives better patient outcomes by applying deep biomarker expertise to research & clinical development strategies, combining the strengths of Cerba Research and ACT Genomics. We are enabled by cutting edge technologies in Flow Cytometry (FCM), Immunohistochemistry (IHC), and PBMC/cell isolations, while functioning as a central laboratory in the APAC region. Working with biotech, pharma, government and nongovernmental organizations, our team is ready to turn precision medicine into action!
Download the flyer to learn more on CerbACT Asia’s capabilities.
Precision Medicine in Practice for Non-Small Cell Lung Cancer (NSCLC)
At the 16th Biomarkers UK Congress in November 2021, Rania Gaspo, PhD gave a talk on implementing precision medicine for Non-Small Cell Lung Cancer. How can you bring precision medicine into practice? What roles can Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and ctDNA play?
Webinar: Turning Precision Medicine into Action in Immuno-Oncology
The challenges in immuno-oncology (I/O) drug development require deep scientific insights, generation and analysis of complex biological data, new state-of-the art technologies and both logistical & operational support across continents. The goal of immuno-oncology drug developers is to turn precision medicine into action, bringing life-changing therapies to patients.
In this webinar originally held on October 4 our experts discuss the use of Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Flow Cytometry (FCM) within immuno-oncology, and how they can offer the comprehensive insights required for I/O clinical trials.
- Jérôme Sallette, PhD, CSO Cerba Research
- Shu Jen Chen, PhD, CSO ACT Genomics
- Sofie Vandevyver, PhD, Head of Business Operations & Marketing Cerba Research
- George Wei, PhD, Vice President R&D ACT Genomics
- Renaud Burrer, PhD, Head of Histopathology Cerba Research
- Nithianandan Selliah, PhD, Global Head Flow Cytometry Cerba Research
Submit your information below to watch the webinar or to download the slide deck to receive our expert’s insights.
Conducting Clinical Trials During COVID-19: Lessons for the Next Pandemic
The coronavirus is not the first infectious disease that has forced clinical trials to adapt. Zika, Ebola, and other diseases called for the world to adjust and collaborate global research efforts. With COVID-19, the rapid spread and impact on global healthcare systems forced us to change our trial management and accelerate our processes like never before. The global research community have already discovered and developed several tests and vaccines in record time through collaboration. Yet we are still working on predictive biomarker testing to identify people who are at the most risk of developing severe symptoms, epidemiological, vaccine, and genetic studies.
To facilitate testing, research, and innovation and to ensure trials continued, Cerba Research and Cerba Healthcare adapted our capabilities and facilities to push research continuity.
Register for this webinar to learn the answers to these questions:
- Did we succeed, how fast did we adapt, and are we ready to face a new pandemic crisis in the future?
- How did we maintain the high security and confidence of testing, and what did our reactivity and proactivity mean in the context of a health crisis?
Webinar: Leveraging Medical Laboratory Data for Patient Recruitment
Connecting real-world laboratory data from clinical sites and digitalizing patient data – the power of Decentralized Clinical Trials (DCT) to change the trials of tomorrow
Digitalization continues to provide an impetus to move away from centralized, high-cost and difficult-to-access settings to more virtual, patient-centric and decentralized clinical trial (DCT) models. Our methods need to be more patient-centric, and we need to collaborate to find remote solutions.
Thanks to digitization, we can now decentralize clinical trials and put patient data in front of research success. In partnership with Biokortex, Cerba Research will show participants of this webinar a picture of the future: how clinical trials will look tomorrow. New technologies allow us to imagine a whole new process for drug development and assays. This new way of thinking reduces costs and enhance access to data. The world is evolving fast, and we need to develop accordingly. Agility, adaptability and digitization need to be the new keywords for a more manageable and secure development.
Watch the recording of our webinar held in April 2021 to learn more!
Immunohistochemistry (IHC): Increase the Success of Biomarker Integration in Clinical Development
“With immunohistochemistry (IHC) technology, biomarkers can be identified in tumor biopsies. IHC provides the possibility to better understand biomarker mechanisms in the tumor’s environment. By implementing a robust biomarker validation process, you can increase the success of biomarker integration in clinical development.”
– Amanda Finan, PhD, Head IHC/Histology R&D and Clinical Validations at Cerba Research
Pediatric Phase I/II Clinical Trial on Mucopolysaccharidosis type III (MPSIIIA)
Lab support for a global pediatric trial for the rare genetic neurodegenerative disorder, Mucopolysaccharidosis type III. Cerba Research provided safety testing, sample management, and specialized testing in our histology lab. Read the case study to discover more details.
Pediatric Phase I/II/III Study in X-Linked Myotubular Myopathy (XLMTM)
Lab support for a global pediatric trial for the rare neuromuscular disease, Myotubular Myopathy. Cerba Research provides safety testing, PBMC isolation, biomarkers, and sample management for the clinical trial. Read more on the challenges and solutions in the case study.